Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
WALTHAM, Mass., Nov. 21, 2016 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison, M.D., will present at the 28th Annual Piper Jaffray Healthcare Conference on November 30, 2016 at 9:50 am EST at the Lotte New York Palace Hotel.
A live webcast of the Company’s presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to potentially enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. For more information on Syndax, please visit www.syndax.com.
Investor Contacts Heather Savelle Argot Partners [email protected] Tel 646.395.3734 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
